SCHEMBL1306477

SCHEMBL1306477

NCc1ccc(Cl)cc1OCCO

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
CYP2A6 P11509 1/20 0.40
LOX P28300 1/20 0.40
AOC3 Q16853 1/20 0.40
CCR5 P51681 1/20 0.38
S1PR4 O95977 1/20 0.38
HTR2C P28335 2/20 0.38
HTR2B P41595 2/20 0.38
HTR2A P28223 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPT P10636 1/20 0.37
IDO1 P14902 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306792 0.92 LMNA (0.48) ALDH1A1LMNACYP2A6LOXAOC3
SCHEMBL8139318 0.83 ALDH1A1 (0.45) ALDH1A1LMNAS1PR4HTR2AKCNH2
SCHEMBL1308077 0.81 HTR2C (0.50) ALDH1A1LMNACYP2A6CCR5S1PR4
SCHEMBL1308133 0.80 HTT (0.46) ALDH1A1LMNACYP2A6S1PR4HTR2C
SCHEMBL1306905 0.79 KDM4E (0.49) ALDH1A1LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL18641892 0.79 CHRM1 (0.50) ALDH1A1LMNAMAPTTP53MAPK1
SCHEMBL16544019 0.79 HTR2C (0.47) ALDH1A1CYP2A6AOC3CCR5HTR2C
SCHEMBL5094816 0.79 ALDH1A1 (0.47) ALDH1A1LMNAS1PR4MAPTTP53
SCHEMBL10359297 0.78 ALDH1A1 (0.68) ALDH1A1LMNAS1PR4MAPTTP53
SCHEMBL13743842 0.78 ALDH1A1 (0.44) ALDH1A1LMNAS1PR4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053457-B2 3-imidazolyl-indoles for the treatment of proliferative diseases NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US disclosed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP disclosed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 ALDH1A1 2589/4885LMNA 2574/4885CYP2A6 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.